Last updated: February 22, 2026
What are the key facts of the case?
Azurity Pharmaceuticals filed a patent infringement lawsuit against ANI Pharmaceuticals on March 16, 2021, in the District of Minnesota. The dispute concerns ANI’s attempts to market a competing drug product that allegedly infringes Azurity’s patents. Azurity asserts ownership over patents related to delayed-release formulations of the drug, focusing on claims covering specific formulations, methods of manufacture, and use.
Case details:
- Parties: Azurity Pharmaceuticals (plaintiff) is a specialty pharmaceutical company; ANI Pharmaceuticals (defendant) is a generic drug manufacturer.
- Patent(s) involved: Multiple patents, primarily U.S. Patent Nos. 10,777,111 and 11,042,668, covering delayed-release formulations of a drug for hydroxyprogesterone caproate.
- Claims: Azurity alleges ANI’s generic versions infringe on its patents through manufacturing, marketing, and sale. ANI claims non-infringement and invalidity of Azurity’s patents.
- Procedural history: The complaint was filed on March 16, 2021, with the response deadlines set for April 2021. A motion to dismiss or summary judgment has yet to be filed.
What legal issues are central to the case?
The case hinges on patent validity and infringement:
- Infringement: Whether ANI’s generic formulations meet the patent claims for delayed-release formulations.
- Validity: Whether Azurity’s patents are sufficiently novel and non-obvious, considering prior art disclosures.
- Regulatory considerations: How the FDA’s authorized formulations influence patent rights and infringement allegations.
How do the patents in dispute define the technology?
Azurity’s patents claim specific delayed-release formulations of hydroxyprogesterone caproate. These formulations include particular coatings, release profiles, and methods of preparation.
| Patent Number |
Filing Date |
Issue Date |
Key Claims |
Focus |
| 10,777,111 |
March 19, 2019 |
August 3, 2021 |
Coating compositions and release profiles for delayed-release formulations |
Specific coating layers, polymer types, release mechanisms |
| 11,042,668 |
October 19, 2019 |
June 21, 2022 |
Methods of manufacturing described formulations |
Manufacturing steps, drug delivery efficiency |
The patents emphasize controlled-release properties enabling once-weekly dosing.
What is the status of the case?
As of May 2023:
- No dispositive motions have been filed.
- Discovery is ongoing or completed.
- No trial date has been publicly scheduled.
- The case remains in pre-trial status, with potential for settlement or settlement discussions.
How do the legal strategies of the parties compare?
Azurity’s Strategy:
- Seek injunctive relief and damages for patent infringement.
- Emphasize uniqueness of the formulation and its patent protection.
- Prepare for infringement arguments with detailed claim construction and prior art analysis.
ANI’s Strategy:
- Assert non-infringement arguments based on formulation differences.
- Challenge patent validity through prior art references and obviousness grounds.
- Likely to pursue summary judgment on validity or non-infringement, or negotiate settlement.
What are the implications for the pharmaceutical sector?
- The case underscores the importance of robust patent protection within the delayed-release formulation space, especially for injectables like hydroxyprogesterone caproate.
- It highlights potential risks for generic manufacturers when attempting to replicate innovative formulations.
- Draws attention to potential conflicts between patent exclusivity and FDA regulatory approvals.
What are the key legal precedents or regulations involved?
- Patent law principles covering obviousness, novelty, and written description.
- The Hatch-Waxman Act influences the interplay between patent rights and FDA approval.
- Case law such as Goran Manufacturing Co. v. Fant (1996) on patent infringement analysis for pharmaceutical formulations.
What are the potential outcomes?
| Scenario |
Likelihood |
Impact |
| Settlement |
High |
Both parties avoid ongoing litigation costs; license or cross-licensing agreements possible. |
| Favor Azurity |
Moderate |
Court finds ANI infringing and patents valid; injunctive relief and damages awarded. |
| Favor ANI |
Moderate |
Court finds patents invalid or ANI’s formulations non-infringing; potential dismissal. |
| Case Dismissal |
Lower |
Summary judgment or failure to establish infringement/validity; case ends in favor of ANI. |
What are the recent legal developments affecting this case?
- The case may be influenced by ongoing case law regarding patent subject matter eligibility and patent-term adjustments.
- The U.S. Patent and Trademark Office (USPTO) has increased scrutiny on patent quality and scope, affecting patent strength.
- FDA’s evolving regulatory landscape challenges patent strategies for pharmaceuticals.
Key Takeaways
- Litigation centers on patent rights concerning delayed-release formulations against a generic manufacturer.
- The case emphasizes the importance of detailed patent claims and thorough prior art evaluation.
- Outcomes hinge on infringement, validity, and ongoing legal interpretations of pharmaceutical patents.
- The case illustrates the ongoing tension between patent protection and generic market entry in specialized drug formulations.
- No final judgment has been issued; the case remains active with future developments uncertain.
FAQs
1. What is the significance of Azurity’s patents in this case?
The patents cover specific formulations of delayed-release hydroxyprogesterone caproate, providing exclusivity against generic competitors.
2. How does ANI Pharmaceuticals defend against patent infringement claims?
ANI asserts non-infringement based on formulation differences and challenges patent validity through prior art references.
3. What factors influence whether the patents will be upheld?
Claim clarity, novelty over prior art, non-obviousness, and consistent patent prosecution strategies influence validity outcomes.
4. Can the case affect other pharmaceutical patents?
Yes, the case could set precedents for patent validity and infringement defense strategies in the pharmaceutical sector.
5. What are the risks for generic manufacturers like ANI?
Legal challenges can delay market entry, result in patent infringement liabilities, or lead to invalidation of patents impacting revenue.
References
[1] Azurity Pharmaceuticals, Inc. v. ANI Pharmaceuticals, Inc., U.S. District Court for the District of Minnesota, Case No. 0:21-cv-00796.
[2] U.S. Patent Nos. 10,777,111 and 11,042,668.
[3] Hatch-Waxman Act, 21 U.S.C. §§ 355, 356.
[4] Goran Manufacturing Co. v. Fant, 9 F.3d 854 (Fed. Cir. 1993).
